Skip to content
AnalystLens

CITIGROUP INC 8-K Report, Corporate Update (Jul 2, 2025)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed July 2, 2025
Period End
July 1, 2025
Securities
CC-PNC-PR
In the record · 2016–202610-K1110-Q328-K279

C filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 279 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Apr ’22Apr ’22
  2. Leadership change8-K · May ’26May ’26

Summary

Summary of the 8-K filed July 2, 2025. Cited figures are marked; the original filing is the authoritative source.

On July 1, 2025, Citigroup announced it completed the Federal Reserve's 2025 annual supervisory stress test.

The preliminary indicative Stress Capital Buffer (SCB) requirement falls to 3.6%a from 4.1%, a 50 basis point decrease, and the preliminary Standardized CET1 regulatory requirement falls to 11.6% from 12.1%. Citi's Standardized CET1 ratio was 13.4% as of March 31, 2025, roughly 130 basis points above the 12.1% requirement in effect at that time. The Federal Reserve will issue Citi's final SCB later in the quarter, so the figures disclosed here remain provisional.

The filing also outlines planned capital returns. Citi intends to raise its quarterly common stock dividend from $0.56 to $0.60b per share starting in the third quarter of 2025, subject to quarterly Board approval. Citi also has a $20 billion multi-year share repurchase program, launched in January 2025, under which $3.75 billion had been repurchased year-to-date as of the filing.

Together, a lower capital requirement and a higher payout signal management's confidence in its capital position and a shift toward returning excess capital to shareholders. For investors, the key takeaways are the lower regulatory burden, the dividend increase of about 7%c, and continued buybacks. The filing's forward-looking statements caution that the final SCB, actual capital levels, and capital actions may differ materially, citing macroeconomic conditions, ongoing regulatory proceedings and consent orders, and evolving capital rules.

Key Highlights

  1. Preliminary SCB requirement decreases 50 bps to 3.6% from 4.1%, pending final Federal Reserve determination later in Q3 2025.
  2. Preliminary Standardized CET1 regulatory requirement decreases 50 bps to 11.6% from 12.1%.
  3. Citi's Standardized CET1 ratio was 13.4% as of March 31, 2025, 130 bps above the 12.1% requirement.
  4. Quarterly common stock dividend to increase about 7% to $0.60 from $0.56 per share, starting Q3 2025, subject to quarterly Board approval.
  5. $20 billion multi-year share repurchase program launched January 2025; $3.75 billion repurchased year-to-date.
  6. Filing is a routine Item 8.01 disclosure following the Fed stress test, with Exhibit 99.1 covering the cover page securities registration information.

Frequently Asked Questions

  1. What does a lower Stress Capital Buffer mean for Citigroup?

    A lower SCB reduces the minimum CET1 capital Citi must hold above regulatory minimums, which frees up capital for dividends, buybacks, or growth. The indicative SCB drops from 4.1% to 3.6%, though the final figure is still pending from the Federal Reserve.

  2. Is the dividend increase guaranteed?

    No. The increase to $0.60 per share from $0.56 is planned for the third quarter of 2025 but requires quarterly approval by Citi's Board of Directors.

  3. How much capital headroom does Citi have above its requirement?

    As of March 31, 2025, Citi's Standardized CET1 ratio of 13.4% was about 130 basis points above the 12.1% requirement then in effect. Against the preliminary 11.6% requirement, the headroom would be larger, though this is based on March 2025 data and not a current position.

  4. How much of the $20 billion buyback has Citi completed?

    As of the filing, Citi had repurchased $3.75 billion year-to-date under the multi-year $20 billion program that began in January 2025, leaving roughly $16.25 billion remaining under the program.

  5. What risks could change these capital plans?

    The filing cites macroeconomic uncertainty, the outcome of extensive regulatory proceedings, examinations, and consent orders, and changes to regulatory capital rules. Any of these could cause the final SCB, capital levels, or capital actions to differ materially from the stated plans.